Email This

Optimizing TKI Therapies: Balancing Efficacy and Adverse Events CME

Michael W. N. Deininger, MD, PhD Author Information and Disclosures

Release Date: March 19, 2008; Valid for credit through March 19, 2009

Credits Available

Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

This CME activity is based on transcripts and slides of presentations delivered by faculty at the "Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors: Clinical Considerations and Interactive Case Studies" symposium, held at the Georgia World Congress Center in Atlanta, Georgia, on December 7, 2007.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Optimizing TKI Therapies: Balancing Efficacy and Adverse EventsMichael W. N. Deininger, MD, PhD

Go to CME Test Questions

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Adequately diagnose and risk-stratify patients with CML;
Initiate and monitor standard treatment regimens;
Understand how to recognize and manage common adverse events;
Modify therapeutic strategy based on patient outcomes.

Author Disclosures

Michael W. N. Deininger, MD, PhD
Disclosure: Grants/Research Support: Calistoga Pharmaceuticals, Cytopia, SGX Pharmaceuticals, TargeGen. Consultant: Bristol-Myers Squibb Company, Novartis Pharmaceuticals. Speakers Bureau: Bristol-Myers Squibb Company

SciMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SciMed designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider